XML 47 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Development, Commercialization and Supply Agreement - Additional Information (Detail 1) - Out-licenses - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-01-01	Dec. 31, 2019
Eddingpharm
License And Collaboration Agreements [Line Items]
Revenue recognized over remaining period	15 years
HLS
License And Collaboration Agreements [Line Items]
Revenue recognized over remaining period	11 years

X

- Definition

License And Collaboration Agreements [Line Items]

+ References

No definition available.

+ Details

Name:	amrn_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix:	amrn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	amrn_BusinessDevelopmentsAxis=amrn_EddingpharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrn_OutLicensesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	amrn_BusinessDevelopmentsAxis=amrn_HLSTherapeuticsIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: